Modus Therapeutics has been granted two patents in the US covering its proprietary compound sevuparin.
More specifically the two patents have been granted claims for the substance sevuparin per se and a manufacturing method for producing sevuparin (U.S. Patent no. 9,480,701) as well as its use in e.g. Sickle Cell Disease (U.S. Patent No. 9.480,702).
The two US patents granted by the United States Patent and Trademark Office (USPTO) will provide key intellectual property protection in the US for Modus’ candidate drug sevuparin until at least December 2032, with the possibility for up to five years’ extension after a market approval. Corresponding patent applications have been submitted in a broad range of other territories including Europe, Asia and Latin America.
Modus is currently enrolling SCD patients into a multi-centre, international, randomised Phase II study in Europe and the Middle East. This proof-of-concept study is designed to demonstrate reduced time to resolution of Vaso-Occlusive Crises (VOC) in SCD patients.
“The grant of these two U.S. patents is a major milestone for Modus as they provide important IP protection for sevuparin and its use for SCD. The US, with 100,000 SCD patients, represents a significant opportunity for sevuparin,” says Christina Herder, CEO of Modus Therapeutics.
